Incyte Q2 revenue rises 16% to $1.2 billion; GAAP profit $405 million; guidance raised
Incyte reported second-quarter 2025 total revenues of $1,216 million, up 16% from a year earlier, and GAAP net income of $405 million, compared with a loss of $444.6 million in the prior-year quarter. The company raised its full-year 2025 guidance for Jakafi and other oncology net product revenues, while absorbing a $242.3 million charge from its contract dispute settlement with Novartis.
Key points
- Total revenues were $1,216 million in Q2 2025, up 16% year over year; Jakafi net product revenues were $764 million, up 8%.
- GAAP diluted EPS was $2.04, compared with a loss of $2.04 per share in Q2 2024.
- Full-year 2025 Jakafi net product revenue guidance was raised to $3,000-$3,050 million from $2,950-$3,000 million; other oncology guidance was raised to $500-$520 million from $415-$455 million.
- The Novartis contract dispute settlement led to a $242.3 million difference recorded in contract dispute settlement expense; Incyte paid Novartis $280.0 million.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.